Patient support and adherence
Genesis Research Group Appoints Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR
Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence...
Moving Beyond the Pill: Unlocking Value Through Engaged, Empowered, and Educated Patients
True "beyond-the-pill" strategy requires shifting from a prescriptive model to a supportive one—using personalized digital tools and authentic patient voices to drive adherence, improve outcomes, and prove value.
Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it...
The silent drop-off: How disengagement shows up in everyday behaviour
In healthcare, disengagement rarely announces itself. It doesn’t always appear as refusal or a clear decision to stop treatment. More often, it shows up quietly, in what is delayed, avoided...
Eli Lilly to acquire Kelonia Therapeutics in deal worth up to $7bn
The acquisition will help Lilly to expand its capabilities in cell and gene therapy
Why patient-centricity depends on site-centricity in clinical trials
Explore why patient-centricity in clinical trials relies on site-centricity, emphasising the need to design trials that empower site teams to better support patients.
Smarter Learning and Better Outcomes: How AI Can Provide an Advantage in Medical Education
See how AI-powered patient avatars allow physicians to test complex diagnoses and treatment plans in a simulated environment.
New Webinar: 2026 Engagement Strategies For Modern Pharma
Turn interaction into intelligence! Don’t miss this chance to lead the industry with our free pharma-exclusive webinar!
MFN Pricing Is Moving Fast – Here’s What Matters
With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it's a lot to digest. In a new...
ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment
In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on...
